Compare SND & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SND | NBP |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 318 | 30 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.2M | 173.5M |
| IPO Year | 2016 | N/A |
| Metric | SND | NBP |
|---|---|---|
| Price | $4.66 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 357.6K | ★ 491.7K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.76 | $1.46 |
| 52 Week High | $5.92 | $5.19 |
| Indicator | SND | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 41.38 |
| Support Level | $4.62 | N/A |
| Resistance Level | $5.75 | $1.67 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 11.42 | 42.42 |
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.